Teva (TEVA) shares 2025 outlook tied to 44th J.P. Morgan Healthcare event

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Limited furnished an update on its expected performance for the 2025 fiscal year in connection with its presentation at the 44th Annual J.P. Morgan Healthcare Conference. On January 11, 2026, the company issued a press release outlining these expectations ahead of its January 13, 2026 conference presentation, and attached that release as an exhibit. The information is being provided to regulators for disclosure purposes and is expressly designated as furnished rather than filed under U.S. securities laws.

False000081868600008186862026-01-112026-01-11iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  January 11, 2026

_______________________________

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Exact name of registrant as specified in its charter)

_______________________________

Israel	001-16174	Not Applicable
(State or other jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

124 Dvora Hanevi’a Street

Tel Aviv 6944020, Israel

(Address of Principal Executive Offices, including Zip Code)

+972-3-914-8213

(Registrant's Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
American Depositary Shares, each representing one Ordinary Share	TEVA	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On January 11, 2026, Teva Pharmaceutical Industries Ltd. (the “Company”) issued a press release (the “Press Release”) in connection with the Company’s presentation on Tuesday, January 13, 2026 at the 44th Annual J.P. Morgan Healthcare Conference. The Press Release includes the Company’s expectations regarding its performance for the 2025 fiscal year. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and the information contained therein is incorporated herein by reference.

The information included in this Item 2.02 is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description of Document
99.1		Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivers Growth and Transforms through Innovation
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Date: January 11, 2026	By:	/s/ Eli Kalif
		Eli Kalif
		Executive Vice President, Chief Financial Officer

FAQ

What did Teva (TEVA) disclose in this 8-K filing?

Teva Pharmaceutical Industries Limited disclosed that it issued a press release on January 11, 2026 outlining its expectations for its performance for the 2025 fiscal year, in connection with an upcoming investor conference presentation.

Which event is Teva (TEVA) participating in according to this filing?

Teva is presenting at the 44th Annual J.P. Morgan Healthcare Conference, with its presentation scheduled for Tuesday, January 13, 2026.

What time period does Teva’s guidance in the press release cover?

The press release described in the filing includes Teva’s expectations regarding its performance for the 2025 fiscal year.

How is the press release treated under U.S. securities laws?

The company states that the information in Item 2.02, including the press release, is being furnished to the SEC and is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934.

Which exhibit contains Teva’s 2025 outlook press release?

Exhibit 99.1 contains the press release titled “Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivers Growth and Transforms through Innovation.”

Who signed this Teva (TEVA) current report on Form 8-K?

The report was signed on behalf of Teva Pharmaceutical Industries Limited by Eli Kalif, Executive Vice President and Chief Financial Officer, dated January 11, 2026.